Drug Development:Vela Laboratories and Anagnostics enter strategic partnership

PRLog (Press Release) - Feb. 9, 2012 - Companionship in clinical studies: patient stratification by cost-effective compact sequencing is a first step.
Affinity and Immunogenicity: hybcell as an alternative to SPR (surface plasmon resonance) technology for larger sample collectives will be tested and positioned.

Viennese Vela Laboratories are among the leading companies offering efficacy and release testing for biopharmaceuticals under GMP conditions (Good Manufacturing Practice). Vela Laboratories and Anagnostics have agreed upon a strategic partnership in the fields of analytical services and marketing and sales in the area of services for drug discovery units.
‘The fast growing demand in the field of Biosimilars - Comparability Testing results in a need for creative business models. Vela obtained international reputation within the market for complete characterisation of Biopharmaceuticals, Biologics and Biosimilars and is among the top tier suppliers of ICH Q6B conform protein analytics. Anagnostics hybcell technology offers totally new analytical solutions, which we want to offer our customers. Together we can serve our customers more efficiently and comprehensively’ comments Dr. Markus Fido, CEO of Vela Laboratories, the decision of his company.
‘Synergies stemming from Anagnostics’ innovative analytical approaches and the outstanding expertise of Vela Laboratories enable Anagnostics to speed up the market penetration in the field of drug discovery’, is highlighted by Christoph Reschreiter, CEO of Anagnostics Bioanalysis GmbH.

Patient stratification / Affinity Measurement
In a first step Anagnostics’ compact sequencing should be applied for patient stratification during clinical studies – for example a test for mutations in the KRAS and BRAF gene.
In a second step Anagnostics’ affinity and immunogenicity measurement will be applied for the characterisation of drug candidates. In comparison to state of the art methods like SPR (surface plasmon resonance) hybcell offers far more capacity for simultaneous examinations of samples and is less vulnerable to interferences (higher selectivity). Another aspect is the ability of hybcell tests to be stored over long periods of time. Especially for long-term projects this aspect could be an advantage for researchers, as they can compare new drug candidates under the same conditions that were applied for examinations earlier in the project.

Leading services for efficacy and release testing of biopharmaceuticals
Vela Laboratories is an internationally active GMP certified contract research/analytics laboratory. Vela offers a broad portfolio of analytical methods, especially for characterisation of proteins. Vela Laboratories offer customer specific analytical services. The highly motivated team of experts focuses on assay development and quality control to serve customers in pre-clinical and clinical developments (market approvals).
www.vela-labs.at

Multiplex diagnostics focusing on routine test in drug discovery and clinical diagnostics.
Austrian Anagnostics Bioanalysis focuses on development and production of systems and tests for analytics in drug development (affinity, immunogenicity…) and clinical diagnostics (drugs of abuse, oncology and severe infections…). The combination of DNA- and protein tests on the same device (hyborg) enables innovative and efficient diagnostic solutions for the rapidly growing demand driven by personalized medicine.

Since 2005 a young team around molecular geneticist and biochemist Dr. Bernhard Ronacher develops multiplexed analytical systems (hyborg) and tests (hybcells). The patented hybcell is the world’s first cylindrical microarray and core of Anagnostics’ technology. Based on this hybcell, complete test kits are assembled and fully automated processed by hyborg.
www.anagnostics.com

Anagnostics Bioanalysis GmbH | Mag. Christoph Reschreiter
A-4300 St. Valentin | Westbahnstraße 55
c.reschreiter@anagnostics.com | Tel. +43 (0)7435 58193-0

Photo:
http://www.prlog.org/11794539/1